LONDON--(BUSINESS WIRE)--Technavio has announced their latest analysis report on drug pipeline for tardive dyskinesia. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat tardive dyskinesia.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Tardive dyskinesia: Market overview
Tardive dyskinesia is a socially stigmatizing long-term side effect, which may occur with certain antipsychotic medications that are generally prescribed for conditions such as schizophrenia and schizoaffective disorder.
According to a senior market research analyst at Technavio, “Tardive dyskinesia syndrome is characterized by repetitive, involuntary, and jerking movements in the face, neck, and tongue. The symptoms of tardive dyskinesia can be very troubling for patients and family members. The muscle movements of the patient, especially in the face, neck, and tongue get out of control.”
Tardive dyskinesia: Segmentation analysis
This pipeline analysis report segments the tardive dyskinesia market based on therapies employed (monotherapy), RoA (oral), therapeutic modality (small molecule), targets (VMAT2, dopamine receptor, and purinergic P2 receptor), MoA (VMAT2 inhibitor, dopamine receptor agonist, and purinergic P2 receptor antagonist), geographical segmentation (Czech Republic, Germany, Hungary, Japan, Poland, Slovakia, and the US) and recruitment status (active, not recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on the mechanism of action, around 50% of the molecules that are being investigated for the treatment of tardive dyskinesia are VMAT2 inhibitors.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.